Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis

CompletedOBSERVATIONAL
Enrollment

544

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

August 23, 2023

Study Completion Date

December 28, 2023

Conditions
Sepsis
Interventions
DEVICE

Blood sampling

Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).

Trial Locations (5)

40513

University of Kentucky, Lexington

43608

Mercy Health St. Vincent, Toledo

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago

02904

Rhode Island Hospital, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Avania

INDUSTRY

lead

Abionic SA

INDUSTRY